Introduction
Bladder cancer (BC) causes significant morbidity and mortality throughout the world, with~380 000 new cases diagnosed and 150 000 BC-related deaths each year [1] . The progression of BC is clearly time-dependent, and it is therefore intuitive that a longer delay in diagnosis and treatment may negatively impact survival.
In a retrospective analysis of >29 000 patients with BC, increased delay from presentation to a doctor with haematuria to BC diagnosis correlated strongly with reduced survival [2] . The median survival dropped from 71 months if the delay was <3 months, to 51 months if the delay was >9 months, and it was calculated that each extra day of delay was associated with a 1% increase in risk of BC-related death [2] . Similarly, in a prospective cohort study of >1 500 patients with BC a delay of >2 weeks from symptom onset to referral to a urologist was associated with a 5% reduction in 5-year survival [3] . While other studies have not been able to show a link between delay and survival, this may be because the relationship between the two is quite complex [3, 4] . For example, patients with less favourable pathology are more likely to be prioritised for assessment and treatment based on factors such as their symptom severity or the cystoscopic appearance of their tumour [3] . Alarmingly, BC is the only cancer in Australia in which survival is deteriorating; 5-year survival has dropped from 68% to 58% over the past 30 years [5] . While significant strides are being made in the treatment of BC within Australia [6, 7] , it may be that more concerted efforts to reduce delay in the assessment and treatment of these patients may help in reversing this concerning trend. The present study therefore sought to quantify and examine the causes of delays in the diagnosis and initial treatment of patients with BC in an Australian population.
Subjects and Methods
All attendances at a one-stop haematuria clinic at a public tertiary-level hospital in Western Australia, between May 2008 and April 2014, were reviewed retrospectively to identify all patients diagnosed with a bladder tumour over this period. This 6-year period extended from when this one-stop haematuria clinic commenced until the time of initial analysis.
Proforma-led, semi-structured telephone interviews were conducted, of both the patient and their GP, and additional data were collected from electronic records and clinical notes as required. Data were collected regarding demographics, histopathology, presentation, investigation, referral, assessment, initial treatment, and patient knowledge and attitudes. De-identified data were recorded in a passwordprotected database.
A primary analysis was conducted of all participants in the study, and a sub-analysis was conducted of all patients with visible haematuria in whom waiting times to diagnosis and initial treatment were able to be calculated. Participants who did not present with visible haematuria were excluded from this sub-analysis because it was not possible to determine the date of onset of their symptoms, or therefore calculate delays they encountered thereafter.
Pre-referral waiting times were composed of 'missed opportunity' waiting times (time from previous presentation to a doctor with haematuria that did not result in urological referral to the recurrence of visible haematuria), patient waiting times (time from first noticing haematuria to seeing a doctor), and referral waiting times (time from first seeing a doctor to being referred). Assessment waiting times were composed of administrative waiting times (time from referral being sent to the referral being received) and clinic waiting times (time from receipt of referral to haematuria clinic). Treatment waiting time was defined as the time from haematuria clinic to surgery.
A flow diagram of recruitment to the study, and participants included in the primary and sub-analyses is shown in Fig. 1 
Results
Between May 2008 and April 2014 there were 1 365 attendances at the one-stop haematuria clinic; 151 patients were diagnosed with a bladder tumour, and 100 of these were both suitable and agreed to participate in the study. The data collected on these 100 patients in the primary analysis relating to patient characteristics, presentation, investigation, referral, histopathology, and patient knowledge and attitudes are summarised in Table 1. Three points arising from these data warrant highlighting. Firstly, despite almost all the patients having a prior diagnosis of urothelial cancer, 21% stated that they were still smoking at the time of their interview. Secondly, haematuria that was ultimately found to be due to a bladder tumour was often relatively short-lived, lasting <24 h for 47% of patients and lasting only one void in 21% of patients. Thirdly, participant awareness about BC prior to diagnosis was relatively poor; only 32% of patients had previously heard of BC and only 43% had known that haematuria may be due to cancer.
A sub-analysis was conducted of the delay in the diagnosis and initial treatment of bladder tumours in 72 patients who presented with visible haematuria and in whom delay was able to be calculated. A summary of this sub-analysis is given in Table 2 , and the distribution of waiting times is shown in Fig. 2 . The median (range) waiting time from initial haematuria to surgery was 69.5 (9-1 165) days. This was comprised of a median pre-referral waiting time of 12 days, assessment waiting time of 23.5 days, and treatment waiting time of 20 days. No longer alive (29) Unable to communicate (9) Unable to contact (8) Patient preference (5) Primary Analysis 28 Excluded:
Visible haematuria but unable to calculate delays (11) Non-visible haematuria (9) Tumour incidentally detected on imaging (8) 72 Participants
Sub-analysis Although pre-referral waiting time was the shortest contributor to total waiting time in this study on average, if long delays were encountered before referral they were often more extensive. As a result of this phenomenon, when the total number of days of waiting time for all patients combined was examined per category, pre-referral delays accounted for 64% of the total. Alarmingly, 21% of patients waited >2 weeks from first noticing haematuria to presenting to a doctor, and 14% of patients reported 'missed opportunity' delays (wherein they had previously presented to a doctor with visible haematuria, often many months earlier, but had not been referred to a urologist). The most contributory factors for pre-referral delays, as determined by the investigators based on the telephone interviews, are presented in Table 3 .
While post-referral delays only accounted for 36% of the total number of days of waiting time for all patients combined, when average delays were examined then post-referral delays were significantly longer than those encountered pre-referral. Concerningly, 36% of patients waited >30 days to be assessed for visible haematuria and 25% of patients waited >30 days to undergo initial treatment. Also, administrative delays were a significant contributor, which accounted for 4.3% of the total number of days of waiting time for all patients combined.
Discussion
As can be seen in Table 4 [3,9-13], the median delays reported in the present study are comparable to other series. Our present treatment delay compares particularly favourably, although this may simply reflect the fact that cystoscopy occurred at initial assessment in our series (and therefore waiting time to diagnostic cystoscopy did not contribute to treatment delay as it did in other series). Although not directly comparable, our median assessment delay of 23.5 days compares favourably to a contemporaneous Australian series of 305 patients referred for investigation of haematuria [8] . In that comparative series the median delay to initial assessment of patients with visible haematuria was 33 days, with these patients experiencing an additional median delay of 27 days to cystoscopy [8] .
Nonetheless, several patients in our present series had extensive delays in the diagnosis and initial treatment of their BC. The various strategies that could be employed to target reductions in pre-referral and post-referral delays in Australia and New Zealand therefore warrant discussion. While some of these strategies lend themselves to coordination at a local level, others may require a recognised organisation to institute policy or advocate for change at a binational level. Although concerns have been raised recently about the public profile of urologists and the USANZ [14] , this organisation would seem best placed to address this problem through policy and interaction with government groups and other relevant parties.
Pre-referral delays
Public health campaigns, such as the 'Be Clear on Cancer: blood in pee' campaign from the UK [15] , have the potential to reduce pre-referral delays through education and may be warranted based on the poor public awareness about BC encountered in the present study. However, while pilot data showed a 48% increase in BC diagnoses when this campaign was trialled [16] , these results have not been replicated following national rollout of the campaign. At one centre the number of diagnoses actually decreased despite a 92% increase in haematuria referrals [17] .
Improved education of GPs about the significance of visible haematuria is also of paramount importance based on the high incidence of 'missed opportunity' delays in the present series in particular (wherein a previous presentation with visible haematuria did not result in urological referral). Most of these patients were either reassured without further *Pre-referral, 'missed opportunity', patient, and total waiting times included estimates. † 'Missed opportunity' waiting times only existed if the patient reported a previous episode of visible haematuria for which they presented to a doctor, but that did not result in referral to a urologist. 'Missed opportunity' waiting time was defined as the time from this previous presentation to a doctor, to the time that they first noticed haematuria during this subsequent episode that did result in referral. investigation or treated for a presumed UTI or sexuallytransmitted infection during their initial presentation. This apparent reluctance by some GPs to refer patients with visible haematuria to a urologist appears to be an international phenomenon, with referral rates of 64-77% being reported in other studies [18, 19] . While the present study was underpowered to examine gender differences in waiting time, women are known to be at a higher risk of inadequate investigation [20, 21] , delayed referral [20] [21] [22] [23] , and nonreferral [24, 25] for haematuria. This gender disparity was confirmed in a recent systematic review, which also found younger age, non-visible haematuria, and smoking to be associated with a less thorough haematuria evaluation [26] .
One potential solution may be for urologists to advocate for immediate referral of all patients with visible haematuria. While investigation could occur alongside referral, this policy would avoid the situation wherein GPs may be falsely reassured by normal imaging, urine cytology, or a mid-stream urine (MSU) demonstrating infection, which may cause them to defer referral. The high incidence of urological malignancy in patients presenting with visible haematuria [27] , particularly BC that can only be excluded by cystoscopy, may be sufficient to justify this approach. This strategy could be employed through the dissemination of reputable educational resources, or the development of a widely accessible haematuria guideline for GPs in Australia and New Zealand [8] .
Another possible strategy could be the modification of MSU or imaging reports to encourage urological referral if the patient has had visible haematuria. We studied this approach in an online case study-based survey that was distributed to GPs [28] . Although the response rate was low, the modification of MSU reports to encourage urological referral was found to significantly increase the likelihood of referral when compared to standard reports (69% vs 41%, P = 0.02) [28] . This strategy has the advantage of delivering a clear message to GPs precisely when they encounter a patient with haematuria, which for any individual GP is a relatively infrequent event. The high utilisation of MSU (96%) and upper tract imaging (82%) by GPs in the present study adds support to this approach, although we note lower utilisation of these investigations in a contemporaneous Australian series [8] .
Post-referral delays
The extent and causes of post-referral delays will vary significantly between institutions; clinical audit and the identification of strategies to reduce delay at a local level is therefore of paramount importance. While many of these delays may be due to theatre and resource limitations, an example of a relatively easy target for reducing delays may be administrative delays incurred through inefficient referral pathways and hospital systems.
One-stop haematuria clinics are a useful way of streamlining the assessment of patients with haematuria, as they allow patients to undergo complete assessment, including flexible cystoscopy, upon first meeting with a urologist. For example, the introduction of a one-stop haematuria clinic in Western Australia successfully reduced time to cystoscopy by 22% [29] . The previously discussed shorter assessment delays in the present series, as compared to a contemporaneous Australian series [8] , are probably mostly due to the utilisation of a one-stop haematuria clinic model at our centre. This one-stop model can also be successfully applied to the timely diagnosis of other urological malignancies, e.g. a one-stop prostate clinic in Western Australia reduced the waiting time from referral to prostate biopsies by 83% [30] . Table 3 Reasons for pre-referral delays. Another potentially useful strategy could be to introduce and enforce strict targets for the assessment of patients with visible haematuria, or who have had bladder tumours demonstrated on imaging. For example, the introduction of a '2-week wait rule' in the UK for just such patients resulted in a 48% reduction in the assessment delay of patients ultimately found to have BC [13] . In the absence of such a policy change, another strategy that may reduce post-referral delays could be the prioritisation of patients with imagingdetected tumours, positive urine cytology, or significant risk factors for BC for assessment. In hospitals that do not offer a one-stop haematuria clinic this may include booking these patients directly for cystoscopy, and for patients with obvious imaging-detected tumours this may include foregoing diagnostic cystoscopy and booking them directly for treatment during their initial consultation.
Limitations
Firstly, the design of the present study leant itself to the introduction of certain biases. The use of semi-structured telephone questionnaires may have introduced investigator bias; however, we attempted to mitigate this by striving to remain objective and constant during the data collection process. The retrospective nature of the present study may have also introduced recall bias, given that some patients were asked to comment on events from several years earlier.
While this was problematic for some questions, we minimised the effects of this by allowing patients to forego questions they were unsure on and by cross-checking information provided by patients with their electronic records. Secondly, because this was a relatively small single-centre study, in which all patients were assessed through a one-stop haematuria clinic, it may limit applicability to other centres. Given that most Australian centres do not offer a one-stop haematuria clinic service, the assessment times we report in the present study may actually be considerably shorter than those encountered elsewhere. Thirdly, the present study intentionally focused on patients with visible haematuria and therefore is unable to draw any significant conclusions about patients with BC who present in other ways, such as with non-visible haematuria or imaging-detected tumours. Finally, the exclusion of 34% (51/151) of patients with bladder tumours from the present study may have resulted in a misrepresentation of the extent of the delays. For example, over half of these excluded patients had died at the time of the study and some of these deaths were BC-related; it is plausible that delays may have been longer in these deceased patients, and may even have contributed to their mortality.
Conclusion
Many patients experience significant delays in the diagnosis and treatment of their BC in Western Australia, and these data probably reflect or even underestimate national trends.
These concerning data warrant consideration of how delays can be reduced, at both a local and binational level, to improve outcomes for these patients. Potential solutions may include: public health campaigns, GP education, national haematuria guidelines, modification of investigation reports to encourage urological referral, local audit, one-stop haematuria clinics, and waiting list target initiatives.
